This page uses content from Wikipedia and is licensed under CC BY-SA.
The nucleotide-binding oligomerization domain-like receptors, in short NOD-like receptors (NLRs), are intracellular sensors of PAMPs that enter the cell via phagocytosis or pores and DAMPs that are associated with cell stress. They are part of pattern recognition receptors and play key roles in regulation of innate immune response. NLRs can cooperate with Toll-like receptors and regulate inflammatory and apoptotic response. They are found in lymphocytes, macrophages, dendritic cells and also in nonimmune cells, for example in epithelium. NLRs are highly conserved through evolution. Their homologs have been discovered in many different animal species (APAF1)  and also in the plant kingdom (disease-resistance R protein).
NLRs contain 3 domains – central NACHT (NOD or NBD – nucleotide-binding domain) domain, which is common to all NLRs, most of NLRs have also C-terminal leucine-rich repeat (LRR) and variable N-terminal interaction domain. NACHT domain mediates ATP-dependent self-oligomerization and LRR senses the presence of ligand. N-terminal domain is responsible for homotypic protein-protein interaction and it can consist of caspase recruitment domain (CARD), pyrin domain (PYD), acidic transactivating domain or baculovirus inhibitor repeats (BIRs).
Nomenclature and system
Names as CATERPILLER, NOD, NALP, PAN, NACHT, PYPAF were used to describe the NLRs family. The nomenclature was unified by the HUGO Gene Nomenclature Committee in 2008. The family was characterized as NLRs to provide description of the families features – NLR means nucleotide-binding domain and leucine-rich repeat containing gene family.
This system divides NLRs into 4 subfamilies based on the type of N-terminal domain:
NODs subfamily consists of NOD1, NOD2, NOD3, NOD4 with CARD domain, CIITA containing acidic transactivator domain and NOD5 without any N-terminal domain.
The well-described receptors are NOD1 and NOD2. The recognition of their ligands recruits oligomerization of NACHT domain and CARD-CARD interaction with CARD-containing serine-threonin kinase RIP2 which leads to activation of RIP2.
RIP2 mediates the recruitment of kinase TAK1 which phosphorylates and activates IκB kinase. The activation of IκB kinase results in the phosphorylation of inhibitor IκB which releases NF-κB and its nuclear translocation. NF-κB then activates expression of inflammatory cytokines.
Mutations in NOD2 are associated with the Crohn's disease or Blau syndrome.
NLRPs subfamily contains NLRP1-NLRP14 that are characterized by the presence of PYD domain. IPAF subfamily has two members – IPAF with CARD domain and NAIP with BIR domain.
NLRPs and IPAF subfamilies are involved in the formation of the inflammasome. The best characterized inflammasome is NLRP3, the activation through PAMPs or DAMPs leads to the oligomerization. The pyrin domain of NLRs binds to an adaptor protein ASC (PYCARD) via PYD-PYD interaction. ASC contains PYD and CARD domain and links the NLRs to inactive form of caspase 1 through the CARD domain.
All these protein-protein interaction form a complex called the inflammasome. The aggregation of the pro-caspase-1 causes the autocleavage and formation of an active enzyme. Caspase-1 is important for the proteolytic processing of the pro-inflammatory cytokines IL-1β and IL-18.
NLRP3 mutations are responsible for the autoinflammatory disease familial cold autoinflammatory syndrome or Muckle–Wells syndrome.
^Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G (2001). "Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB". J Biol Chem. 276 (7): 4812–8. doi:10.1074/jbc.M008072200. PMID11087742.
^ abInohara N, Ogura Y, Chen FF, Muto A, Nuñez G (2001). "Human Nod1 confers responsiveness to bacterial lipopolysaccharides". J Biol Chem. 276 (4): 2551–4. doi:10.1074/jbc.M009728200. PMID11058605.
^Park JH, Kim YG, McDonald C, Kanneganti TD, Hasegawa M, Body-Malapel M, et al. (2007). "RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs". J Immunol. 178 (4): 2380–6. doi:10.4049/jimmunol.178.4.2380. PMID17277144.
^Okafuji I, Nishikomori R, Kanazawa N, Kambe N, Fujisawa A, Yamazaki S, et al. (2009). "Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis". Arthritis Rheum. 60 (1): 242–50. doi:10.1002/art.24134. PMID19116920.
^Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES (2002). "The PYRIN-CARD protein ASC is an activating adaptor for caspase-1". J Biol Chem. 277 (24): 21119–22. doi:10.1074/jbc.C200179200. PMID11967258.